Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients

Pippa Corrie(University of Cambridge), N. Warner(Churchill Hospital), Sarah P. Blagden(Churchill Hospital), John M. Shaw(University of Saskatchewan), P. Price(Hammersmith Hospital), Sue D’Ath(Addenbrooke's Hospital), A Mayer(Addenbrooke's Hospital), Claire Blesing(Churchill Hospital)

British Journal of Cancer

September 1, 2002

10.1038/sj.bjc.6600523

Cited by 16

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

|The Lancet Oncology|2019|1.2k

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222